Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Status:
Active, not recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Early Phase 1

University of Rochester

Ipilimumab
Nivolumab